Aligos Therapeutics, Inc. (ALGS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 1.5M 3M 4.5M Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 140K Q2 '23: 4.3M Q3 '23: 1.1M Q4 '23: 672K Q1 '24: 694K Q2 '24: 1.1M Q3 '24: 1.2M Q4 '24: 606K Q1 '25: 311K Q2 '25: 965K Q3 '25: 741K Q4 '25: 169K Q1 '26: 2.8M Q2 '26: 0 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '19: -14.5M Q4 '19: -18.4M Q1 '20: -20.7M Q2 '20: -21.3M Q3 '20: -21.6M Q4 '20: -34.3M Q1 '21: -27.7M Q2 '21: -29.6M Q3 '21: -33.1M Q4 '21: -37.9M Q1 '22: -35.6M Q2 '22: -20.4M Q3 '22: -18.9M Q4 '22: -22.7M Q1 '23: -23.9M Q2 '23: -19.1M Q3 '23: -19.1M Q4 '23: -26M Q1 '24: -22M Q2 '24: -26.4M Q3 '24: -20.1M Q4 '24: -20.6M Q1 '25: -19.2M Q2 '25: -18.6M Q3 '25: -28.4M Q4 '25: -21.8M Q1 '26: -26.9M Q2 '26: -1.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '19: -14.1M Q4 '19: -18.2M Q1 '20: -20M Q2 '20: -20.8M Q3 '20: -33.3M Q4 '20: -34.4M Q1 '21: -27.7M Q2 '21: -29.8M Q3 '21: -33.1M Q4 '21: -37.7M Q1 '22: -35.6M Q2 '22: -19.9M Q3 '22: -18.6M Q4 '22: -21.9M Q1 '23: -23M Q2 '23: -18.8M Q3 '23: -18M Q4 '23: -27.9M Q1 '24: -34.9M Q2 '24: 5.1M Q3 '24: -19.3M Q4 '24: -82.2M Q1 '25: 43.1M Q2 '25: -15.9M Q3 '25: -31.5M Q4 '25: -19.9M Q1 '26: -23M Q2 '26: -1.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '19: -15M Q1 '20: -20.3M Q2 '20: -17.7M Q3 '20: -16.6M Q4 '20: -19.7M Q1 '21: -29.8M Q2 '21: -23M Q3 '21: -25.4M Q4 '21: -37.5M Q1 '22: -20.4M Q2 '22: -25M Q3 '22: -17.1M Q4 '22: -16.8M Q1 '23: -22.4M Q2 '23: -13.6M Q3 '23: -20.3M Q4 '23: -22.7M Q1 '24: -22.7M Q2 '24: -19.5M Q3 '24: -20.1M Q4 '24: -18.4M Q1 '25: -20.9M Q2 '25: -15.5M Q3 '25: -24.3M Q4 '25: -21.7M Q1 '26: -23.1M Q2 '26: -24.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '19: -15.7M Q1 '20: -21.4M Q2 '20: -18.3M Q3 '20: -16.9M Q4 '20: -19.7M Q1 '21: -30.1M Q2 '21: -23.2M Q3 '21: -25.5M Q4 '21: -37.8M Q1 '22: -20.9M Q2 '22: -25.4M Q3 '22: -17.1M Q4 '22: -16.9M Q1 '23: -22.4M Q1 '20 Q3 '20 Q1 '21 Q3 '21 Q1 '22 Q3 '22 Q1 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q3 '21: 42.4M Q1 '22: 42.5M Q2 '22: 42.7M Q3 '22: 42.8M Q1 '23: 42.9M Q2 '23: 43.2M Q3 '23: 1.7M Q1 '24: 6.2M Q2 '24: 6.3M Q3 '24: 6.3M Q1 '25: 8.7M Q2 '25: 10.4M Q3 '25: 10.4M Q1 '26: 10.4M Q2 '26: 10.4M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q2 '20: -29.34 Q3 '20: -33.60 Q4 '20: -10.87 Q1 '21: -4.05 Q2 '21: 2.56 Q3 '21: 12.78 Q4 '21: -3.22 Q1 '22: -3.32 Q2 '22: -3.00 Q3 '22: -2.66 Q4 '22: -2.26 Q1 '23: -1.95 Q2 '23: -1.91 Q3 '23: -11.84 Q4 '23: -10.94 Q1 '24: -15.99 Q2 '24: -14.75 Q3 '24: -7.45 Q4 '24: -20.94 Q1 '25: -17.47 Q2 '25: -19.81 Q3 '25: -19.78 Q4 '25: -2.45 Q1 '26: -2.55 Q2 '26: -1.16 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.